REVATIO
Drug
PFIZER INC.
Total Payments
$614,124
Transactions
99
Doctors
6
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7,854 | 10 | 1 |
| 2021 | $20,391 | 5 | 0 |
| 2020 | $52,678 | 29 | 1 |
| 2019 | $416,755 | 14 | 4 |
| 2018 | $32,978 | 19 | 1 |
| 2017 | $83,467 | 22 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $601,008 | 75 | 97.9% |
| Travel and Lodging | $10,743 | 16 | 1.7% |
| Food and Beverage | $2,043 | 7 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $330.00 | 1 | 0.1% |
Payments by Type
Research
$601,008
75 transactions
General
$13,116
24 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SAFETY OF SILDENAFIL IN PREMATURE INFANTS AT RISK OF BRONCHOPULMONARY DYSPLASIA | PFIZER INC. | $411,824 | 0 |
| A MULTICENTRE RANDOMIZED PLACEBOCONTROLLED DOUBLEBLIND TWOARMED PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN PPHN OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN WITH A LONG TERM FOLLOWUP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT | PFIZER INC. | $95,968 | 0 |
| A MULTINATIONAL MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION PAH | PFIZER INC. | $89,042 | 0 |
| SILDENAFIL CITRATE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) | Mylan Specialty L.P. | $975.00 | 0 |
Top Doctors Receiving Payments for REVATIO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $597,808 | 74 |
| , M.D | Cardiovascular Disease | Torrance, CA | $7,854 | 10 |
| , MD | Neonatal-Perinatal Medicine | Washington, DC | $3,574 | 2 |
| , MD | Pediatrics | Stanford, CA | $1,720 | 4 |
| , MD | Pediatrics | Chapel Hill, NC | $1,571 | 4 |
| , MD | Pediatric Pulmonology | Aurora, CO | $1,266 | 4 |
| , M.D | Specialist | Pasadena, CA | $330.00 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $605,295
- Mylan Inc. $7,854
- Mylan Specialty L.P. $975.00
Product Information
- Type Drug
- Total Payments $614,124
- Total Doctors 6
- Transactions 99
About REVATIO
REVATIO is a drug associated with $614,124 in payments to 6 healthcare providers, recorded across 99 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2024. In 2024, $7,854 was paid across 10 transactions to 1 doctors.
The most common payment nature for REVATIO is "Unspecified" ($601,008, 97.9% of total).
REVATIO is associated with 5 research studies, including "SAFETY OF SILDENAFIL IN PREMATURE INFANTS AT RISK OF BRONCHOPULMONARY DYSPLASIA" ($411,824).